Projet CareHD (Horizon 2020, appel à projets 2017)
Action : Staff Exchanges
Panel : Social Sciences and Humanities
Statut du projet : SIGNED

HD is a monogentic disease, meaning modification in a single gene occurring in all cells of the body. In Western countries it is estimated that 5-7 people per 100,000 are affected by HD. Currently there is no cure for the disease and effective management is key to quality of life for those who are affected. Patients and families who are living with the disease face multiple social and self-management issues. For example, stigma of the disease alongside social isolation have been key drivers in terms of high levels of mental health difficulties. CH has the ability to assist with many of the difficulties faced by HD, RD and indeed other symptom related diseases. For example, CH can monitor and identify key intervention points along the disease progression pathway, it can inform and facilitate integrated care, it can assist with joining key stakeholders together in a shared ecosystem, and importantly it can assist patients and their families in terms of reducing isolation, optimising self-management and thus increasing empowerment and self-actualisation. Further, CH has the ability to optimise scarce resources in an over stretched health care system and thus produce effective and efficient outcomes. The primary aim of this RISE project is to establish an international and inter-sectoral network of organisations working in collaboration on a research project which seeks to design a technology enabled patient centred care pathway which will identify how to optimise Connected Health (CH) interventions at key points along Huntington’s Disease (HD) trajectory. This is an important project because patient centred care from a CH perspective in the area of HD is currently under developed. This project aims to develop a new pathway of patient care based upon a better understanding of what type of technology can assist patients with improving their quality of life at various key points along the care pathway.

Mots clés : connected health, patient centred care, huntington s disease, rare diseases

Participants :
- Huntington's disease association of ireland (Irlande) — Partner, beneficiary, Autres, subvention : 81000.0 €
- Icon clinical research sarl (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 94500.0 €
- University of Ulm (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 0.0 €
- National University of Ireland (Irlande) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 247500.0 €
- Comtrade programske resitve doo (Slovénie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 54000.0 €
- Icon clinical research limited (Irlande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 27000.0 €
- The scottish huntington s association (Royaume-Uni) — Partner, beneficiary, Autres, subvention : 40500.0 €
- National University of Ireland (Irlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 121500.0 €
- University of Aberdeen (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 0.0 €
- University of Reading (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 121500.0 €
- University College London Hospitals NHS Foundation Trust (Royaume-Uni) — Partner, beneficiary, Recherche, subvention : 40500.0 €